FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

429611006: Lanreotide acetate (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2008. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
2691550013 Lanreotide acetate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
2692194013 Lanreotide acetate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
35081000188116 lanréotide acétate fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
819881000172116 acétate de lanréotide fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Lanreotide acetate (substance) Is a Lanreotide (substance) false Inferred relationship Some
Lanreotide acetate (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Hypothalamic inhibiting factor (disposition) true Inferred relationship Some
Lanreotide acetate (substance) Is a Somatostatin analog (substance) true Inferred relationship Some
Lanreotide acetate (substance) This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Lanreotide (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Lanreotide 120mg/0.5mL prefilled syringe The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Lanreotide acetate (substance) Inferred relationship Some
Lanreotide 60mg/0.3mL prefilled syringe The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Lanreotide acetate (substance) Inferred relationship Some
Lanreotide 90mg/0.3mL prefilled syringe The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Lanreotide acetate (substance) Inferred relationship Some
Lanreotide 30mg powder and solvent for injection suspension vial The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. False Lanreotide acetate (substance) Inferred relationship Some
Lanreotide (as lanreotide acetate) 30 mg powder for suspension for injection vial The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Lanreotide acetate (substance) Inferred relationship Some 1
Product containing precisely lanreotide (as lanreotide acetate) 180 milligram/1 milliliter conventional release solution for injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Lanreotide acetate (substance) Inferred relationship Some 1
Lanreotide (as lanreotide acetate) 120 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Lanreotide acetate (substance) Inferred relationship Some 1
Lanreotide (as lanreotide acetate) 240 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Lanreotide acetate (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start